Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Overview of attention for article published in Cancer Discovery, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 1 news outlet
twitter: 52 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 141 Dimensions

Readers on

mendeley: 87 Mendeley

Summary News X Wikipedia Dimensions citations

So far, Altmetric has seen 75 X posts from 52 X users, with an upper bound of 469,903 followers.

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study https://t.co/hV38DOAcrF #ScientiaVH

08 Jun 2023

Reply Repost Favourite

RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q

24 Oct 2022

Reply Repost Favourite

RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q

19 Oct 2022

Reply Repost Favourite

RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q

16 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 71 additional X posts.